ATE478062T1 - Zusammensetzungen und verfahren zur in vivo abbildung von loeslichen beta-amyloid - Google Patents
Zusammensetzungen und verfahren zur in vivo abbildung von loeslichen beta-amyloidInfo
- Publication number
- ATE478062T1 ATE478062T1 AT04750543T AT04750543T ATE478062T1 AT E478062 T1 ATE478062 T1 AT E478062T1 AT 04750543 T AT04750543 T AT 04750543T AT 04750543 T AT04750543 T AT 04750543T AT E478062 T1 ATE478062 T1 AT E478062T1
- Authority
- AT
- Austria
- Prior art keywords
- amyloid
- vivo
- imaging
- compositions
- methods
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 title 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 title 1
- 238000003384 imaging method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 101800001718 Amyloid-beta protein Proteins 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012216 imaging agent Substances 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/431,202 US20040223912A1 (en) | 2003-05-07 | 2003-05-07 | Compositions and methods for non-invasive imaging of soluble beta-amyloid |
| US10/747,715 US20040223909A1 (en) | 2003-05-07 | 2003-12-26 | Compositions and methods for non-invasive imaging of soluble beta-amyloid |
| PCT/US2004/012559 WO2004100998A2 (en) | 2003-05-07 | 2004-04-23 | Compositions and methods for non-invasive imaging of soluble beta-amyloid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE478062T1 true ATE478062T1 (de) | 2010-09-15 |
Family
ID=33416408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04750543T ATE478062T1 (de) | 2003-05-07 | 2004-04-23 | Zusammensetzungen und verfahren zur in vivo abbildung von loeslichen beta-amyloid |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20040223912A1 (de) |
| JP (1) | JP4831421B2 (de) |
| AT (1) | ATE478062T1 (de) |
| DE (1) | DE602004028731D1 (de) |
| ES (1) | ES2348870T3 (de) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| WO2007027963A2 (en) * | 2005-08-30 | 2007-03-08 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of screening bifunctional molecules for modulated pharmacokinetic properties |
| PT1954718E (pt) | 2005-11-30 | 2014-12-16 | Abbvie Inc | Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos |
| KR20180058863A (ko) | 2005-11-30 | 2018-06-01 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
| CA2632822C (en) | 2005-12-12 | 2018-08-28 | Ruth Greferath | A beta 1-42 specific monoclonal antibodies with therapeutic properties |
| JP2009524826A (ja) | 2006-01-26 | 2009-07-02 | ザ ユニヴァーシティー オブ テキサス | 撮像のための方法及び装置 |
| PL2468770T3 (pl) | 2006-07-14 | 2018-07-31 | Ac Immune S.A. | Humanizowane przeciwciało przeciw amyloidowi beta |
| KR100858357B1 (ko) * | 2006-10-02 | 2008-09-11 | (주) 디지탈바이오텍 | 벤조퓨란계 유도체 화합물을 유효성분으로 함유하는인지기능 장애의 예방 및 치료용 조성물 |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| EP2520561B1 (de) | 2007-06-08 | 2016-02-10 | MannKind Corporation | IRE-1a-Inhibitoren |
| US8613923B2 (en) * | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| EP2586795B1 (de) | 2007-10-05 | 2018-05-16 | Genentech, Inc. | Verwendung eines Anti-Amyloid-Beta-Antikörpers bei Augenkrankheiten |
| GB0722650D0 (en) * | 2007-11-19 | 2007-12-27 | Ge Healthcare Ltd | Novel imaging method |
| US20090162280A1 (en) * | 2007-12-20 | 2009-06-25 | General Electric Company | Detecting soluble a-beta |
| ES2544679T3 (es) * | 2007-12-28 | 2015-09-02 | Prothena Biosciences Limited | Tratamiento y profilaxis de la amiloidosis |
| US8193363B2 (en) * | 2008-08-29 | 2012-06-05 | Astrazeneca Ab | Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits |
| US9801865B2 (en) | 2008-09-24 | 2017-10-31 | The United States Of America As Represented By The Department Of Veteran Affairs | Materials and methods for diagnosis, prevention and/or treatment of stress disorders and conditions associated with abeta peptide aggregation |
| US8512677B2 (en) * | 2009-04-27 | 2013-08-20 | Case Western Reserve University | Pyro-glutamate Aβ targeting agents |
| US9198985B2 (en) | 2009-05-22 | 2015-12-01 | Vanderbuilt University | Bimodal star polymer architectures as fluorescent and MRI imaging reagents |
| MX336196B (es) | 2010-04-15 | 2016-01-11 | Abbvie Inc | Proteinas de union a amiloide beta. |
| MY164579A (en) | 2010-07-30 | 2018-01-15 | Ac Immune Sa | Safe and functional humanized antibodies |
| EP3533803B1 (de) | 2010-08-14 | 2021-10-27 | AbbVie Inc. | Anti-amyloid-beta antikörper |
| US10035847B2 (en) | 2013-10-02 | 2018-07-31 | The Rockefeller University | Amyloid protofibril antibodies and methods of use thereof |
| WO2018150276A2 (en) | 2017-02-16 | 2018-08-23 | Universidad San Sebastian | The combination of cotinine plus antioxidant for treatment-resistant depression and correction of astrocytes functional deficit induced by depression and other neuropathological conditions |
| US12352719B2 (en) | 2019-09-20 | 2025-07-08 | KYCERA AVX Components Corporation | Somatic cell-based electrical biosensor |
| CN111072605B (zh) * | 2019-12-17 | 2021-11-02 | 赣南医学院 | 一种氟烷基取代的苯并呋喃衍生物或吲哚衍生物的制备方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4560534A (en) * | 1983-11-02 | 1985-12-24 | Miles Laboratories, Inc. | Polymer catalyst transducers |
| US5811310A (en) * | 1986-09-30 | 1998-09-22 | Albert Einstein College Of Medicine Of Yeshiva Univ. | The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease |
| US5231000A (en) * | 1987-10-08 | 1993-07-27 | The Mclean Hospital | Antibodies to A4 amyloid peptide |
| US6287793B1 (en) * | 1988-08-19 | 2001-09-11 | Elan Pharmaceuticals, Inc. | Diagnostic methods for alzheimer's disease |
| US5434050A (en) * | 1991-08-13 | 1995-07-18 | Regents Of The University Of Minnesota | Labelled β-amyloid peptide and methods of screening for Alzheimer's disease |
| US5272055A (en) * | 1991-12-24 | 1993-12-21 | The University Of Kentucky Research Foundation | Detection of Alzheimer's disease and other diseases using a photoaffinity labeling method |
| US5441870A (en) * | 1992-04-15 | 1995-08-15 | Athena Neurosciences, Inc. | Methods for monitoring cellular processing of β-amyloid precursor protein |
| US5837672A (en) * | 1992-07-10 | 1998-11-17 | Athena Neurosciences, Inc. | Methods and compositions for the detection of soluble β-amyloid peptide |
| WO1994017197A1 (fr) * | 1993-01-25 | 1994-08-04 | Takeda Chemical Industries, Ltd. | ANTICORPS DIRIGE CONTRE LE β-AMYLOIDE OU UN DERIVE DE CE DERNIER ET SON UTILISATION |
| JPH09505465A (ja) * | 1993-09-28 | 1997-06-03 | ザ ジェネラル ホスピタル コーポレイション | 神経増殖を調整し、β／Ａ４アミロイド誘発形態を逆転させる為のアンチセンスオリゴヌクレオチドの使用 |
| US6417178B1 (en) * | 1994-07-19 | 2002-07-09 | University Of Pittsburgh | Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits |
| US6168776B1 (en) * | 1994-07-19 | 2001-01-02 | University Of Pittsburgh | Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
| US6703407B1 (en) * | 1994-09-20 | 2004-03-09 | Eli Lilly And Company | Benzofuran compounds, compositions, and methods |
| US6114133A (en) * | 1994-11-14 | 2000-09-05 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41) |
| US5520904A (en) * | 1995-01-27 | 1996-05-28 | Mallinckrodt Medical, Inc. | Calcium/oxyanion-containing particles with a polymerical alkoxy coating for use in medical diagnostic imaging |
| US5523309A (en) * | 1995-03-10 | 1996-06-04 | Eli Lilly And Company | Benzofuran pharmaceutical compounds |
| EP0866805A1 (de) * | 1995-12-12 | 1998-09-30 | Karolinska Innovations AB | Peptide, das die KLVFF Sequenz von beta-Amyloid bindet |
| US6054114A (en) * | 1996-05-08 | 2000-04-25 | Massachusetts Institute Of Technology | Organometallic ligands for the localization and quantification of amyloid in vivo and in vitro |
| US6274119B1 (en) * | 1998-08-20 | 2001-08-14 | The Regents Of The Univ. Of California | Methods for labeling β-amyloid plaques and neurofibrillary tangles |
| ES2220582T3 (es) * | 1999-12-20 | 2004-12-16 | Eli Lilly And Company | Derivados de piperidina y su uso como antagonistas de receptor de serotonina. |
| AU2001261728A1 (en) * | 2000-05-17 | 2001-11-26 | Bristol-Myers Squibb Pharma Company | Use of small molecule radioligands for diagnostic imaging |
| SI1334091T1 (sl) * | 2000-08-24 | 2013-01-31 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Derivati tioflavina in njihova uporaba pri diagnozi in terapiji pri Alzheimerjevi bolezni |
| AUPR283801A0 (en) * | 2001-02-01 | 2001-03-01 | Australian National University, The | Chemical compounds and methods |
| WO2003018068A1 (en) * | 2001-04-27 | 2003-03-06 | The General Hospital Corporation | Ocular diagnosis of alzheimer's disease |
-
2003
- 2003-05-07 US US10/431,202 patent/US20040223912A1/en not_active Abandoned
- 2003-12-26 US US10/747,715 patent/US20040223909A1/en not_active Abandoned
-
2004
- 2004-04-23 DE DE602004028731T patent/DE602004028731D1/de not_active Expired - Lifetime
- 2004-04-23 ES ES04750543T patent/ES2348870T3/es not_active Expired - Lifetime
- 2004-04-23 AT AT04750543T patent/ATE478062T1/de not_active IP Right Cessation
- 2004-04-23 JP JP2006532458A patent/JP4831421B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE602004028731D1 (de) | 2010-09-30 |
| JP2006528684A (ja) | 2006-12-21 |
| ES2348870T3 (es) | 2010-12-16 |
| US20040223912A1 (en) | 2004-11-11 |
| JP4831421B2 (ja) | 2011-12-07 |
| US20040223909A1 (en) | 2004-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE478062T1 (de) | Zusammensetzungen und verfahren zur in vivo abbildung von loeslichen beta-amyloid | |
| IL180896A0 (en) | Method of tumour imaging | |
| WO2004100998A3 (en) | Compositions and methods for non-invasive imaging of soluble beta-amyloid | |
| ATE461449T1 (de) | Verfahren zum nachweis von medizinisch relevanten zuständen in gelösten lbc-proben | |
| ATE443260T1 (de) | Kontrastmittel und verfahren zum imaging von naaldase oder psma | |
| ATE349446T1 (de) | Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel | |
| DE60233485D1 (de) | Verfahren zur diagnose, behandlung und prävention von knochenverlust | |
| ATE464323T1 (de) | Zusammensetzungen und verfahren für die tumor- diagnose und behandlung | |
| EP1578371A4 (de) | Zusammensetzungen und verfahren für die tumor-diagnose und behandlung | |
| EP1505990A4 (de) | Verfahren zur behandlung von hepatitis | |
| CY1105322T1 (el) | Μεθοδοι και συνθεσεις για την ανιχνευση παθολογικων συμβαντων | |
| ATE376428T1 (de) | Metallkomplexverbindungen | |
| DE602004016499D1 (de) | Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankung | |
| JP5927634B2 (ja) | 多孔質歯科ハイドロキシアパタイトを検出するためのキットおよび方法 | |
| IL175667A (en) | Imaging factor that includes a synthetic caspase-3 inhibitor marked with the neuroimaging agent, a radiopharmaceutical containing it, a kit for preparation of the preparation and a method for diagnosis based on it | |
| DE60035693D1 (de) | Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten | |
| ATE504580T1 (de) | Malonsäureamidderivate als inhibitoren von g- sekretase zur behandlung von alzheimer-krankheit | |
| ATE310736T1 (de) | Verbindungen zur bilddarstellung der alzheimer- krankenheit | |
| DE60221115D1 (de) | Zusammensetzungen und verfahren zur verwendung von fibronektin-fragmenten bei krebsdiagnose | |
| ATE495271T1 (de) | Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin | |
| EP1496743A4 (de) | Zusammensetzungen und verfahren zur therapie und diagnose von lungenkrebs | |
| ATE534037T1 (de) | Verwendung des proteins asc als marker für brustkrebs | |
| ATE438412T1 (de) | Zusammensetzung und verfahren zur medizinischen bilddarstellung von körperhöhlen | |
| WO2012144755A3 (ko) | 리포칼린 2 발현 수준을 측정하는 경도 인지 장애 진단용 조성물, 키트 및 경도인지 장애 진단을 위한 정보 제공방법 | |
| DE60324820D1 (de) | Verfahren zum testen des oxidiertes-ldl-beta-2-glycoprotein-i-komplexes in vivo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |